Beam Therapeutics
ISIN US07373V1052
|WKN A2PY7P
Overview
Description
Beam Therapeutics, Inc. es una empresa de biotecnología dedicada a la creación de una plataforma integrada de medicamentos genéticos de precisión. Su cartera de productos en fase de desarrollo incluye BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301 y BEAM-201. La empresa fue fundada por David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli y J. Keith Joung el 25 de enero de 2017 y tiene su sede en Cambridge, MA.
Salud Biofarmacéuticos Otros biofarmacéuticos Estados Unidos
Financials
Key metrics
| Market capitalisation, EUR | 1.362,19 m |
| EPS, EUR | -4,23 |
| P/B ratio | 1,76 |
| P/E ratio | - |
| Dividend yield | 0,00% |
Income statement (2024)
| Revenue, EUR | 58,72 m |
| Net income, EUR | -348,29 m |
| Profit margin | -593,13% |
What ETF is Beam Therapeutics in?
There are 34 ETFs which contain Beam Therapeutics. All of these ETFs are listed in the table below. The ETF with the largest weighting of Beam Therapeutics is the ARK Genomic Revolution UCITS ETF USD Accumulating.
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
